VERTEX PHARMACEUTICALS INC / MA Cash & Equivalents 2007-2025 | VRTX
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is VERTEX PHARMACEUTICALS INC / MA's current cash & equivalents?
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual cash & equivalents for 2025 was $5.08B, a 11.27% increase from 2024. VERTEX PHARMACEUTICALS INC / MA cash & equivalents for the quarter ending December 31, 2025 was $5.08B.
What was VERTEX PHARMACEUTICALS INC / MA's cash & equivalents in 2024?
VERTEX PHARMACEUTICALS INC / MA annual cash & equivalents for 2024 was $4.57B, a 55.93% decline from 2023.
What was VERTEX PHARMACEUTICALS INC / MA's cash & equivalents in 2023?
VERTEX PHARMACEUTICALS INC / MA annual cash & equivalents for 2023 was $10.37B, a 1.28% decline from 2022.
What is VERTEX PHARMACEUTICALS INC / MA's 5-year cash & equivalents CAGR?
VERTEX PHARMACEUTICALS INC / MA cash & equivalents grew at a compound annual growth rate (CAGR) of 3.22% from FY2020 to FY2025, going from $5.99B to $5.08B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $5.08B | +11.3% | 10-K |
| FY2024 | $4.57B | -55.9% | 10-K |
| FY2023 | $10.37B | -1.3% | 10-K |
| FY2022 | $10.50B | +54.6% | 10-K |
| FY2021 | $6.79B | +13.5% | 10-K |
| FY2020 | $5.99B | +92.6% | 10-K |
| FY2019 | $3.11B | +17.3% | 10-K |
| FY2018 | $2.65B | +59.1% | 10-K |
| FY2017 | $1.67B | +40.7% | 10-K |
| FY2016 | $1.18B | +65.6% | 10-K |
| FY2015 | $714.8M | +14.3% | 10-K |
| FY2014 | $625.3M | +9.8% | 10-K |
| FY2013 | $569.3M | +16.3% | 10-K |
| FY2012 | $489.4M | +3.0% | 10-K |
| FY2011 | $475.3M | +95.4% | 10-K |
| FY2010 | $243.2M | -45.6% | 10-K |
| FY2009 | $446.7M | +14.8% | 10-K |
| FY2008 | $389.1M | +9.4% | 10-K |
| FY2007 | $355.7M | - | 10-K |